Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Revenues for CONCORDBIO are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 6.16800
forwardPE 32.24710
debtToEquity 0.16400
earningsGrowth 0.47800
revenueGrowth 0.34800
grossMargins 0.65191
operatingMargins 0.40896
trailingEps 35.55000
forwardEps 0.00000

CONCORDBIO's current ratio being 6.168 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
With earnings and revenue growth in positive territory, Concord Biotech Limited is projected to expand its business. This strong financial performance suggests the company will continue to grow, as increased profitability and sales drive future success.
CONCORDBIO's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The steady upward revision of Concord Biotech Limited's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about Concord Biotech Limited's future prospects and potential for growth.

Insider Transactions:

Insider Transactions for CONCORDBIO
Insider Transactions for CONCORDBIO


2 sales of CONCORDBIO stock were made, with market price at 1583.050048828125 per share.During the period under consideration, no sell transactions took place.More buys than sells near the current price levels of Concord Biotech Limited might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


CONCORDBIO has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view CONCORDBIO as a reliable choice for their money, offering a promising avenue for future growth and financial gains.